Specify a stock or a cryptocurrency in the search bar to get a summary
Freeline Therapeutics Holdings Plc
FRLNFreeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. Address: Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Analytics
WallStreet Target Price
13.25 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures FRLN
Dividend Analytics FRLN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History FRLN
Stock Valuation FRLN
Financials FRLN
Results | 2019 | Dynamics |